Definitions

Sorry, no definitions found. You may find more data at blinatumomab.

Etymologies

Sorry, no etymologies found.

Support

Help support Wordnik (and make this page ad-free) by adopting the word Blinatumomab.

Examples

  • Known as Blinatumomab, the drug could also have other medical applications and "will serve as an important complement to our oncology pipeline," said retiring Amgen Chief Executive Kevin Sharer in a statement.

    News - latimes.com By Ti 2012

  • Blinatumomab is based on biotechnology that is designed to program the body's immune system to go after tumor cells.

    Amgen to Buy Biotech Micromet for $1.16 Billion Peter Loftus 2012

  • Micromet's share price jumped after the presentation of promising data on Blinatumomab at the ASH meeting.

    Reuters: Press Release 2012

  • Blinatumomab was generally well-tolerated by patients in the Phase 2 study.

    The Earth Times Online Newspaper 2010

  • Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas.

    The Earth Times Online Newspaper 2010

  • Blinatumomab was generally well-tolerated by patients in the Phase 2 study.

    BioSpace.com Featured News and Stories 2010

  • Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas.

    BioSpace.com Featured News and Stories 2010

  • Blinatumomab Adult ALL MRD Study of T cell engagement, is intended to evaluate the efficacy, safety and tolerability of blinatumomab in up to 130 evaluable adult ALL patients with MRD after treatment with front-line chemotherapy.

    Micromet Reports Third Quarter 2010 Financial Results - Yahoo! Finance 2010

  • Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study.

    BioSpace.com Featured News and Stories 2010

  • Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study.

    The Earth Times Online Newspaper 2010

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.